Regulatory Science Symposium: Diversity in Clinical Trials in the Time of COVID-19 Session 7: Ensuring Participant Diversity and Engagement During COVID-19

Research & Study Design
Regulatory & Quality Sciences

Regulatory Science Symposium: Diversity in Clinical Trials in the Time of COVID-19 Session 6: Populations on the Fringe of Clinical Trial Enrollment

Research & Study Design
Regulatory & Quality Sciences

Regulatory Science Symposium: Diversity in Clinical Trials in the Time of COVID-19 Session 5: Diversity, Equity and Inclusion in Clinical Research

Research & Study Design
Regulatory & Quality Sciences

Regulatory Science Symposium: Diversity in Clinical Trials in the Time of COVID-19 Session 4: Clinical Trials Participation: Understanding the Needs and Importance of Diverse Populations

Research & Study Design
Regulatory & Quality Sciences

Regulatory Science Symposium: Diversity in Clinical Trials in the Time of COVID-19 Session 3: FDA Initiatives to Address Diversity in Clinical Trials

Regulatory & Quality Sciences

Regulatory Science Symposium: Diversity in Clinical Trials in the Time of COVID-19 Session 2: What Do We Mean by Diversity in Clinical Trials?

Research & Study Design
Regulatory & Quality Sciences

Regulatory Science Symposium: Diversity in Clinical Trials in the Time of COVID-19 Session 1: Introduction

Regulatory & Quality Sciences

Overcoming Regulatory Challenges and Building Community Trust for a SARS-CoV-2 Vaccine

Learn more about the FDA and regulatory restrictions related to SARS-CoV-2 vaccines and the challenges in distribution to the general public

Regulatory & Quality Sciences
Communication, Dissemination, & Teamwork

NIH Funding Acknowledgment: Important - All publications resulting from the utilization of SC CTSI resources are required to credit the SC CTSI grant by including the NIH funding acknowledgment and must comply with the NIH Public Access Policy.